How can you deal with the ‘collision' between capital/business interests and political/fiscal interests, which come to the fore in cross-border merger and acquisitions?
As the economies in the UK and other parts of Europe begin to stabilize after the financial crisis, merger and acquisition activity has started to pick up. With that, European companies are increasingly becoming the targets of large, sometimes unsolicited takeover bids by non-EU headquartered companies. This has begun raising national political issues in the countries in which the targets are headquartered. In the UK, Pfizer’s £69bn failed takeover proposal for AstraZeneca in recent months reignited the debate regarding public interest tests, and other protectionist measures against atte...
To continue reading this article...
Join Investment Week for free
Signup and gain exclusive members-only insights - all free of charge!
- Unlimited access to real-time news, analysis and opinion from the investment industry, including the Sustainable Hub covering fund news from the ESG space
- Get ahead of regulatory and technological changes affecting fund management
- Important and breaking news stories selected by the editors delivered straight to your inbox each day
- Weekly members-only newsletter with exclusive opinion pieces from leading industry experts
- Be the first to hear about our extensive events schedule and awards programmes
